EUVIMEDEUVIMED entdecken
Crossref

Current trend in pharmaceutical law in EU

María Dolores Cabezas

Pharmaceuticals Policy and Law · 2012

DOI: 10.3233/ppl-120354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals Policy and Law, 2012. Verfasst von María Dolores Cabezas.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major progress has been achieved over the last years in EU. Legislative initiatives have led to improved marketing authorisation procedures, the harmonisation of data protection in the EU, better access to medicines for children, and a new regulatory framework for advanced therapies. Nevertheless stakeholders continue to raise concerns with regard to the market fragmentation linked to disparities in national pricing and reimbursement schemes, unnecessary regulatory burdens caused by divergences in the implementation of Community legislation, and divergence in interpreting the relevant legislation and cumbersome procedures for multi-centre clinical trails in different Member States. New legislation are preparing. Establishing and enforcing international public health standards is essential to minimise the risk that unsafe products enter the EU market.

Zitieren

APA

Cabezas, M. D. (2012). Current trend in pharmaceutical law in EU. Pharmaceuticals Policy and Law. https://doi.org/10.3233/ppl-120354

Vancouver

Cabezas MD. Current trend in pharmaceutical law in EU. Pharmaceuticals Policy and Law. 2012. doi:10.3233/ppl-120354

BibTeX
@article{Cabezas2012,
  author = {Cabezas, María Dolores},
  title = {Current trend in pharmaceutical law in EU},
  journal = {Pharmaceuticals Policy and Law},
  year = {2012},
  doi = {10.3233/ppl-120354}
}
Kostenlos starten →